ChinaDrugStatus

China Drug Approvals & Reimbursement

Search China drug approvals and reimbursement listings by generic name, Chinese name, brand, or approval number.

Try

2026 catalogs published Nov 14, 2026·Effective Jan 1, 2027

Latest verified changes

20 verified records

Launch sample covering 20 drugs across 2026 NRDL additions, 6-month transition removals, payment scope expansions, and Commercial List updates (2025 vs 2026).Sample scope & sources

Mazdutide玛仕度肽
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Added

Newly added to 2026 NRDL Negotiated List (#30, Class B, price redacted *); restricted to adults with Type 2 Diabetes mellitus (weight management indication not reimbursed).

▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Added

Newly added to 2026 NRDL Negotiated List (#297, Class B, *) across 3 lymphoma indications (r/r LBCL, r/r FL, r/r MCL); transitioned out of the 2025 Commercial List (#12).

Insulin icodec / Semaglutide依柯胰岛素司美格鲁肽
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Added

Newly added to 2026 NRDL Negotiated List (#18, Class B, *) for adult T2D inadequately controlled on basal insulin or GLP-1 receptor agonist.

Zolbetuximab佐妥昔单抗
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Added

Newly added to 2026 NRDL Negotiated List (#287, Class B, *) for first-line CLDN18.2+ HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with chemo.

Datopotamab deruxtecan德达博妥单抗
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Added

Newly added to 2026 NRDL Negotiated List (#288, Class B, *) for adult HR+/HER2- unresectable or metastatic breast cancer after prior ET and ≥1L chemo.

Sapropterin dihydrochloride盐酸沙丙蝶呤
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Added

Newly added to 2026 NRDL Negotiated List (#42, Class B, ¥62.00 per 100mg tablet) for BH4-deficiency HPA; transitioned from the 2025 Commercial List (#2).

Pamiparib帕米帕利
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Removed (Transition)

Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #256); 6-month transition period under original payment standard runs through Jun 30, 2027.

6-month transition period through Jun 30, 2027.

Beraprost sodium (sustained-release)贝前列素钠缓释片
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Removed (Transition)

Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #40); 6-month transition period under original payment standard runs through Jun 30, 2027.

6-month transition period through Jun 30, 2027.

Xiao'er Niuhuang Qingxin San小儿牛黄清心散
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Removed (Transition)

Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #20); 6-month transition period under original payment standard runs through Jun 30, 2027.

6-month transition period through Jun 30, 2027.

Shenlong Ningxin Capsules参龙宁心胶囊
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
NRDL Removed (Transition)

Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #26); 6-month transition period under original payment standard runs through Jun 30, 2027.

6-month transition period through Jun 30, 2027.

Dupilumab度普利尤单抗
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Payment Scope Changed

Expanded from 1 indication (atopic dermatitis) in 2025 (#93) to 5 indications in 2026 (#104): added prurigo nodularis, asthma (≥6y), eosinophilic COPD, and bullous pemphigoid.

Trastuzumab deruxtecan德曲妥珠单抗
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Payment Scope Changed

Expanded from 2 breast cancer settings in 2025 (#228) to 7 indications in 2026 (#255), adding HR+ HER2-low/ultralow BC, neoadjuvant HER2+ BC, 2L/3L+ HER2+ gastric/GEJ, and HER2-mutant NSCLC.

Sacituzumab tirumotecan芦康沙妥珠单抗
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Payment Scope Changed

Expanded from 2 indications in 2025 (#252) to 4 indications in 2026 (#284), adding HR+/HER2- breast cancer (post-ET/chemo) and earlier post-EGFR-TKI non-squamous NSCLC.

Ivosidenib艾伏尼布
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Payment Scope Changed

Expanded beyond r/r IDH1-mutated AML in 2025 (#258) to add first-line newly diagnosed IDH1-mutated AML combined with azacitidine (age ≥75 or intensive-chemo ineligible) in 2026 (#298).

Eliglustat tartrate酒石酸艾格司他
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Payment Scope Changed

Expanded from adult Gaucher disease type 1 in 2025 (#38, ¥381.00) to add pediatric GD1 patients (age ≥6y, weight ≥15kg, ERT-stable) in 2026 (#41, ¥361.95 per 84mg capsule).

▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Commercial List Added

Adult PSMA-positive mCRPC: (1) After progression on ARPI and eligible to delay chemotherapy; (2) After progression on ARPI and taxane-based chemotherapy.

Tofersen托夫生
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Commercial List Added

Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Eplontersen sodium依普隆特生钠
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Commercial List Added

Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Commercial List Expanded

Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy.

Tazemetostat hydrobromide氢溴酸他泽司他
▾
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Commercial List Removed

Listed in 2025 Commercial List (#16); not carried into the 2026 Commercial List or 2026 NRDL.